Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIPC Combined With Acetazolamide for AMS Prevention
NCT05023941Phase 4Completed
- Start
- Dec 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of acetazolamide in acute mountain sickness (AMS). Started Dec 2021; status: completed.
02
Drugs
acetazolamide
03
Conditions
acute mountain sickness (AMS)
Beyond the preview
Go deeper on NCT05023941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05023941.